Stent

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Stenosis, Clinical trial, NAMSA, NSPR, Food, Nasdaq, MDR, Partnership, Travel, CAD, IDE, Holocene, TCAR, CRO, Host, TEL, Nine Months, EPS, Conference, Patient, Growth, TCT, Stent, CEO, FDA, Stroke, Fine chemical, Pharmaceutical industry, Video game, Medical device, EU

TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease (CAD) and prevention of stroke today announced financial and operating results for the third quarter ended September 30, 2022.

Key Points: 
  • Financial Results for the Third Quarter ended September 30, 2022
    For the third quarter of 2022, total revenue increased 33.6%, to $1,431,000, from $1,071,000 during the third quarter of 2021.
  • Gross profit for the third quarter of 2022 increased by $274,000, or 297.8%, to $366,000, compared to a gross profit of $92,000 for the third quarter of 2021.
  • Total operating expenses for the third quarter of 2022, were $4,976,000, an increase of $853,000, or 20.7% compared to $4,123,000 for the third quarter of 2021.
  • Management will host a conference call at 8:30AM ET today, November 8th, to review financial results and provide an update on corporate developments.

Endologix Reports Five-Year Data of the LEOPARD Trial at 2022 Vascular InterVentional Advances (VIVA) Conference

Retrieved on: 
Thursday, November 3, 2022
Health, Clinical Trials, Medical Devices, Freedom, Randomized controlled trial, Mortality, AFX, EVAR, Rupture, Sale, RCT, Industry, Vascular disease, Conference, Use-centered design, CEO, Patient safety, Aortic aneurysm, Medicine, Stent, Acquisition, ARC, Society, Patient, Medical imaging, Pharmaceutical industry, MD

Endologix LLC , a privately held global medical device company dedicated to improving patients lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the five-year results from the LEOPARD randomized controlled trial.

Key Points: 
  • Endologix LLC , a privately held global medical device company dedicated to improving patients lives by providing disruptive therapies for the interventional treatment of vascular disease, announced the five-year results from the LEOPARD randomized controlled trial.
  • LEOPARD was a prospective multi-center trial designed to directly compare the anatomically fixated AFX2 Endovascular AAA System and the predecessor AFX device, to commercially available endografts with proximal fixation.
  • The LEOPARD trial enrolled 455 patients across 56 US Centers.
  • These products are designed to treat a wide spectrum of vascular disease from abdominal aortic aneurysms to lower limb peripheral vascular disease.

Led by Legend Capital, Easy-Flow Raises Tens of Millions of CNY in Angel Round

Retrieved on: 
Tuesday, November 1, 2022
Marketing, CNY, Moyamoya disease, Research, D, Disease, R, Health, Catheter, UNPRI, USD, Artery, Varicose veins, FDA, Patient, RMB, Conditional sentence, ESG, VC, Stent, Angel, Solution, Pharmaceutical industry

HONG KONG, Nov 1, 2022 - (ACN Newswire) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital.

Key Points: 
  • HONG KONG, Nov 1, 2022 - (ACN Newswire) - Shanghai Easy-Flow ("Easy-Flow") recently completed its Angel financing round by raising tens of millions of CNY, led by Legend Capital.
  • Founded in November 2021, Easy-Flow is committed to efficiently creating a complete set of solutions in the field of peripheral interventional devices.
  • The company develops products such as drug balloons, catheters, stents, and thrombus removal equipment for treating peripheral arteriovenous diseases.
  • Regarding this financing round, Joe ZHOU, managing director of Legend Capital, said: " Legend Capital has long focused on investment in medical devices.

$32.2 Billion Global Interventional Cardiology Devices Market Report to 2027: Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, October 28, 2022
Medical Devices, Health, CAD, Diabetes, OCT, Plaque, Degenerative disease, TMR, Prevalence, Growth, Arrhythmia, Catheter, Hemostasis, Angioplasty, Atherectomy, Stent, COVID-19, CABG, Coronary artery disease, FFR, MI, IVUS, Hypertension, Solution, Pharmaceutical industry, Medical imaging

Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting.

Key Points: 
  • Interventional cardiology devices refer to the medical equipment and guiding tools used for performing cardiovascular procedures, such as angioplasty and stenting.
  • Some of the commonly used devices include angioplasty balloons, stents, mitral, pulmonary and tricuspid valves, catheters, plaque modification and hemodynamic flow alteration devices.
  • Interventional cardiology and embolic protection devices are widely used to capture embolic debris to ensure continuous blood flow and preventing blockages.
  • The publisher provides an analysis of the key trends in each sub-segment of the global interventional cardiology devices market, along with forecasts at the global, regional and country level from 2022-2027.

Think tank’ develops proposals to leverage precision medicine to improve cholangiocarcinoma patient outcomes

Retrieved on: 
Tuesday, October 25, 2022
Quality of life, Method, Lung, Caregiver, Cholangiocarcinoma, Stent, Sidney Kimmel, Disease, Therapy, Bile duct, Neoplasm, Bile, Diagnosis, Science, List of American Medical Association journals, Education, JAMA Network Open, Foundation, Patient, Biology, Primary sclerosing cholangitis, Research, Colonoscopy, Sidney Kimmel Comprehensive Cancer Center, Precision medicine, Cancer, Gallbladder, Roy Taylor (scientist), Incidence, Awareness, Liver, Survival, GLOBE, Smoker, CCA, PSC, CCF, Cohort study, Leadership, Medical device, Medical imaging, Pharmaceutical industry, Vaccine

This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.

Key Points: 
  • This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.
  • The primary themes precision prevention, early detection, and precision therapeutics reflected areas of urgency and opportunity for improving outcomes for people impacted by CCA.
  • Cholangiocarcinoma is a type of cancer that forms in the slender tubes called bile ducts that carry the digestive fluid bile.
  • Its mission is to find a cure for cholangiocarcinoma (bile duct cancer) and improve the quality of life for patients.

Global Biomaterials Market Report (2022 to 2031) - Players Include Carpenter Technology, Corbion, Evonik Industries, Royal DSM and Berkeley Advanced Biomaterials - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022
Health, Biotechnology, Benchmark, Adoption, Hypertension, Stent, Breast implant, DSM (company), Prevalence, Growth, Ophthalmology, Wound healing, BASF, Evonik Industries, Carpenter Technology Corporation, Celanese, Smoking, Organization, 3D, Hospital, Tissue, Medtronic, SE, Heart, Coronavirus, Partnership, Infarction, Technology, Corbion, Cardiovascular disease, Acquisition, Industry, Incidence, Degenerative disease, Diabetes, Create, BASF SE, Ceramic, Tissue engineering, CeramTec, Marketing, Pharmaceutical industry, Silk

Outperform competitors using forecast data and the drivers and trends shaping the market.

Key Points: 
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • The regions covered in the biomaterials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The biomaterials market research report is one of a series of new reports that provides biomaterials market statistics, including biomaterials industry global market size, regional shares, competitors with a biomaterials market share, detailed biomaterials market segments, market trends and opportunities, and any further data you may need to thrive in the biomaterials industry.
  • The countries covered in the biomaterials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium

Retrieved on: 
Thursday, October 20, 2022
Health, Surgery, Clinical Trials, Medical Devices, Sale, Technology, Anatomy, Patient, EVAR, Society for Vascular Surgery, ISSN, Multimedia, Mortality, CT, Vascular disease, MD, Department, Acquisition, JAGUAR, Renal artery, AAAS, CEO, Cleveland Clinic, ALTO, Journal, Randomized controlled trial, AAA, Forward-looking statement, Aortic aneurysm, Stent, FDA, IDE, Medical imaging, Pharmaceutical industry

The study reports the clinical outcomes of the ALTO Abdominal Stent Graft System and highlights the devices safety and effectiveness at one-year post-procedure.

Key Points: 
  • The study reports the clinical outcomes of the ALTO Abdominal Stent Graft System and highlights the devices safety and effectiveness at one-year post-procedure.
  • The study concluded that the Endologix ALTO stent graft is safe and effective in treating AAA with appropriate anatomy at one year.
  • Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients.
  • Endologixs current commercial EVAR products include the AFX2 Endovascular AAA System and the ALTO Abdominal Stent Graft System.

Elixir Medical Expands Leadership Team With Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing

Retrieved on: 
Monday, October 17, 2022
Research, Surgery, Medical Devices, Marketing, Communications, Cardiology, Health, General Health, Science, Elixir, Global marketing, Stent, Thunderbird School of Global Management, Patient, MBA, Medtronic, University of Michigan, Multi-divisional form, Marketing, Doctor of Philosophy, Medicine, Thunderbird, Western Michigan University, Arizona State University, Heart, Leadership, Pharmaceutical industry

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President, Global Marketing.

Key Points: 
  • Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President, Global Marketing.
  • Alex possesses more than 20 years of leadership experience in successfully developing new markets and therapies in interventional cardiology, structural heart, and endovascular businesses worldwide.
  • Most recently, Alex served as Divisional Vice President of Global Marketing for Abbott Vascular, where he was responsible for the long-term strategy and marketing of the division's coronary, endovascular, imaging and physiology portfolios.
  • I am honored to join such a dynamic organization, and excited about becoming a part of the excellent leadership team.

Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems

Retrieved on: 
Monday, October 17, 2022
Health, FDA, Medical Devices, Diabetes, Surgery, Cardiology, Biotechnology, Physician, LinkedIn, Moyamoya disease, Leg, News, Testosterone and the cardiovascular system, Stent, Sale, Plaque, SEC, Prevalence, Organization, NASDAQ, Patient, Hospital, CSI, Twitter, Walking, Annual report, Private Securities Litigation Reform Act, Form 10-K, Knee, PAD, Obesity, Atherectomy, Hematuria, Pain, Incidence, Contraindication, Diabetes, Coronary artery disease, Amputation, Perforation, Dissection, Classic, Diamondback, Heart, Hypotension, FACC, Death, FDA, Max, Risk, Form 10-Q, Pharmaceutical industry, Medical device, MD

Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).

Key Points: 
  • Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).
  • Built on the proven Diamondback 360 Orbital Atherectomy platform, the 2.00 Max Crown is uniquely designed to enable simultaneous modification of both intimal and medial calcium.
  • Said Dr. Srivastava, The new 2.00 Max Crown greatly expands the lesions that can be treated with CSIs Orbital Atherectomy.
  • Our peripheral orbital atherectomy systems can now treat a wider range of plaque morphologies throughout the leg.

Growing Prevalence of Respiratory Disorders Will Push Pulmonology Devices Market to Present Significant Growth During 2020-2030 - Future Market Insights, Inc.

Retrieved on: 
Wednesday, October 19, 2022
Olympus Corporation, Adoption, Stent, COPD, Observation, Prevalence, Growth, Diagnosis, EBUS, CAGR, Silicon, Degenerative disease, Hospital, Asthma, Air pollution, Cystic fibrosis, FMI, Bronchoscopic lung volume reduction (BLVR), Lung cancer, Needle, Safety, Boston Scientific, Lung cancer staging, Lithium, Risk management, Video game, Healthcare, Retail, Walton Micro-Tech Corporation

NEWARK, Del., Oct. 18, 2022 /PRNewswire/ -- The global pulmonology devices market is expected to grow at a steady rate over the forecast period. The market for pulmonology devices will demonstrate substantial growth in the upcoming years. Heightened prevalence of respiratory disorders like asthma, lung cancers, chronic obstructive pulmonary disorders (COPD), and cystic fibrosis fuel the pulmonology devices market to grow at a robust CAGR of about 10.7%during the projected period.

Key Points: 
  • Heightened prevalence of respiratory disorders like asthma, lung cancers, chronic obstructive pulmonary disorders (COPD), and cystic fibrosis fuel the pulmonology devices market to grow at a robust CAGR of about 10.7%during the projected period.
  • Additionally, favorable reimbursement enforced for outpatient procedures is a factor that will positively impact the prospect of the pulmonology devices market.
  • This coupled with heightened demand for such products in the country is driving the growth of the pulmonology devices market in the U.S.
  • The U.K. and Japan are two other countries that are predicted to undergo notable growth in the pulmonology devices market during the forecast period.